Jounce Therapeutics Stock Forecast, Price & News

Jounce Therapeutics (NASDAQ:JNCE) Frequently Asked Questions

Is Jounce Therapeutics a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Jounce Therapeutics in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Jounce Therapeutics stock.
View analyst ratings for Jounce Therapeutics or view top-rated stocks.

How has Jounce Therapeutics' stock been impacted by COVID-19?

Jounce Therapeutics' stock was trading at $4.28 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, JNCE stock has increased by 82.2% and is now trading at $7.80.
View which stocks have been most impacted by COVID-19.

Are investors shorting Jounce Therapeutics?

Jounce Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 887,500 shares, a drop of 38.4% from the October 31st total of 1,440,000 shares. Based on an average daily trading volume, of 484,600 shares, the days-to-cover ratio is presently 1.8 days. Approximately 2.7% of the shares of the stock are sold short.
View Jounce Therapeutics' Short Interest.

When is Jounce Therapeutics' next earnings date?

Jounce Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for Jounce Therapeutics.

How were Jounce Therapeutics' earnings last quarter?

Jounce Therapeutics, Inc. (NASDAQ:JNCE) released its quarterly earnings data on Thursday, November, 4th. The company reported ($0.59) earnings per share for the quarter, missing the consensus estimate of ($0.44) by $0.15. During the same period in the previous year, the company earned ($0.73) EPS.
View Jounce Therapeutics' earnings history.

What price target have analysts set for JNCE?

5 Wall Street analysts have issued 12-month price objectives for Jounce Therapeutics' shares. Their forecasts range from $15.00 to $17.00. On average, they expect Jounce Therapeutics' stock price to reach $15.67 in the next twelve months. This suggests a possible upside of 100.9% from the stock's current price.
View analysts' price targets for Jounce Therapeutics or view top-rated stocks among Wall Street analysts.

Who are Jounce Therapeutics' key executives?

Jounce Therapeutics' management team includes the following people:

• Richard Murray, President, Chief Executive Officer & Director
• Kimberlee Cobleigh Drapkin, Chief Financial Officer & Treasurer
• Elizabeth G. Trehu, Chief Medical Officer (LinkedIn Profile)
• Dmitri Wiederschain, Chief Scientific Officer
• Stephen Farrand, Chief Technical Officer

What is Richard Murray Ph.D's approval rating as Jounce Therapeutics' CEO?

45 employees have rated Jounce Therapeutics CEO Richard Murray Ph.D on Glassdoor.com. Richard Murray Ph.D has an approval rating of 97% among Jounce Therapeutics' employees. This puts Richard Murray Ph.D in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Jounce Therapeutics' key competitors?

Some companies that are related to Jounce Therapeutics include Immunocore (IMCR), Inhibrx (INBX), Coherus BioSciences (CHRS), Replimune Group (REPL), Ocugen (OCGN), REGENXBIO (RGNX), Sangamo Therapeutics (SGMO), iTeos Therapeutics (ITOS), AlloVir (ALVR), Rubius Therapeutics (RUBY), Vaxcyte (PCVX), Caribou Biosciences (CRBU), Humacyte (HUMA), Icosavax (ICVX) and Vaxart (VXRT).
View all of JNCE's competitors.

What other stocks do shareholders of Jounce Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Jounce Therapeutics investors own include Exelixis (EXEL), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), CRISPR Therapeutics (CRSP), Novavax (NVAX), Mylan (MYL), Progenics Pharmaceuticals (PGNX), Adaptimmune Therapeutics (ADAP), Incyte (INCY) and Nektar Therapeutics (NKTR).

When did Jounce Therapeutics IPO?

(JNCE) raised $76 million in an initial public offering (IPO) on Friday, January 27th 2017. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan and Cowen and Company served as the underwriters for the IPO and Wells Fargo Securities and Baird were co-managers.

What is Jounce Therapeutics' stock symbol?

Jounce Therapeutics trades on the NASDAQ under the ticker symbol "JNCE."

Who are Jounce Therapeutics' major shareholders?

Jounce Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include TRV GP II LLC (5.27%), BlackRock Inc. (4.95%), RTW Investments LP (2.72%), Dimensional Fund Advisors LP (2.04%), Goldman Sachs Group Inc. (1.32%) and Geode Capital Management LLC (1.20%). Company insiders that own Jounce Therapeutics stock include Barbara Gayle Duncan, Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third and Rock Ventures Iii LP Third.
View institutional ownership trends for Jounce Therapeutics.

Which major investors are selling Jounce Therapeutics stock?

JNCE stock was sold by a variety of institutional investors in the last quarter, including TRV GP II LLC, Assenagon Asset Management S.A., Credit Suisse AG, Millennium Management LLC, Granahan Investment Management Inc. MA, Dimensional Fund Advisors LP, Marshall Wace LLP, and Two Sigma Investments LP. Company insiders that have sold Jounce Therapeutics company stock in the last year include Elizabeth Trehu, Hugh M Cole, John Duncan Higgons, Kimberlee C Drapkin, Richard /Ca/ Murray, Rock Ventures Ii LP Third, and Rock Ventures Iii LP Third.
View insider buying and selling activity for Jounce Therapeutics or view top insider-selling stocks.

Which major investors are buying Jounce Therapeutics stock?

JNCE stock was purchased by a variety of institutional investors in the last quarter, including RTW Investments LP, Goldman Sachs Group Inc., Moloney Securities Asset Management LLC, Two Sigma Advisers LP, Geode Capital Management LLC, BlackRock Inc., Yorktown Management & Research Co Inc, and Jasper Ridge Partners L.P..
View insider buying and selling activity for Jounce Therapeutics or or view top insider-buying stocks.

How do I buy shares of Jounce Therapeutics?

Shares of JNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Jounce Therapeutics' stock price today?

One share of JNCE stock can currently be purchased for approximately $7.80.

How much money does Jounce Therapeutics make?

Jounce Therapeutics has a market capitalization of $399.70 million and generates $62.34 million in revenue each year. The company earns $-43.84 million in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Jounce Therapeutics have?

Jounce Therapeutics employs 128 workers across the globe.

What is Jounce Therapeutics' official website?

The official website for Jounce Therapeutics is www.jouncetx.com.

Where are Jounce Therapeutics' headquarters?

Jounce Therapeutics is headquartered at 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139.

How can I contact Jounce Therapeutics?

Jounce Therapeutics' mailing address is 780 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The company can be reached via phone at (857) 259-3840 or via email at [email protected].